ATOS · Atossa Therapeutics, Inc.
$2.60
+0.04 (+1.56%)
At close · Aug 14
Going-concern doubt
— flagged Aug 7, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until it becomes profitable. These conditions raise substantial doubt as to the Company's ability to continue as a going concern. ... Although the Company received this infusion of capital, management maintains that in order to alleviate the conditions that raise substantial doubt, the Company will need, among other things, additional capital resources. ... However, management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.”View the 10-Q filed Aug 7, 2026
Market Cap
$25.95M
Shares
9.98M
Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.
No Proposed Sales
No Form 144 proposed-sale notices are available for this stock yet.
Key facts
CIK
1488039
CUSIP
04962H704
13F (30d)
34 filings
34 filers
Visit website
Investor relations